DR. REDDY'S LABORATORIES-ADR
RDYNYSEUS Equity
$12.44▲ $0.30 (+2.43%)
Market closed · at close1h—
24h▲ 2.4%
7d▲ 2.4%
14d▲ 5.8%
30d▼ 3.7%
1y▼ 10.6%
🏦Market Cap
$10.36B
Mid Cap
📈Revenue Growth (YoY)
-0.9%
Declining
📊Gross Margin
61.4%
High
💵FCF Margin
5.5%
Moderate
⚖️P/S Ratio
2.9x
Cheap
Otter Score
45
Weak
Trading Snapshot
- Day Range
- $12.40 – $12.68
- 52-Week Range
- —
- Volume
- $2.32B
- Avg Volume
- $2.32B
- Shares Outstanding
- 833.0M
- Next Earnings
- Oct 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.59B
- Last Q Revenue
- $635M
- P/E Ratio
- 30.3
- P/S Ratio
- 2.9x
- EPS (TTM)
- —
- Dividend Yield
- 0.68%
Why Investors Own RDY
- ✓High-growth profile — revenue up +30.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 54% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$2.59B▲ +27.3% YoY
Gross Margin (TTM)
54.0%▲ +0.6% YoY
Operating Income (TTM)
$736M▲ +27.3% YoY
Free Cash Flow (TTM)
$702M▲ +27.3% YoY
About DR. REDDY'S LABORATORIES-ADR
A company profile for DR. REDDY'S LABORATORIES-ADR isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
45/100
Analyst Price Target
ⓘAverage Target
$13.34
▲ +7.2% Upside
High Target$14.71
Low Target$11.79
Based on 41 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
DR. REDDY'S LABORATORIES-ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift RDY price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
DR. REDDY'S LABORATORIES-ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.